Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company
pharmaphorum
SEPTEMBER 11, 2020
Prior to the $63 billion takeover by AbbVie, Allergan’s biggest product was botulinum toxin product Botox, best known as a wrinkle and migraine treatment, and that headed a sizeable medical aesthetics portfolio at the company which also included dermal filler products like Juvederm.
118 
Let's personalize your content